Literature DB >> 7707318

Novel modified carboxy terminal fragments of neuropeptide Y with high affinity for Y2-type receptors and potent functional antagonism at a Y1-type receptor.

J J Leban1, D Heyer, A Landavazo, J Matthews, A Aulabaugh, A J Daniels.   

Abstract

Peptide analogs of neuropeptide Y (NPY) with a Tyr-32 and Leu-34 replacement resulted in the decapeptide TyrIleAsnLeuIleTyrArgLeuArgTyr-NH2 (9; Table 1) and a 3700-fold improvement in affinity at Y2 (rat brain; IC50 = 8.2 +/- 3 nM) receptors when compared to the native NPY(27-36) C-terminal fragment. In addition, compound 9 was an agonist at Y1 (human erythroleukemia (HEL) cell; ED50 = 8.8 +/- 0.5 nM) receptors with potency comparable to that of NPY(1-36) (ED50 = 5 nM). Molecular dynamics and 1H-NMR were used to propose a solution structure of decapeptide 9 and for subsequent analog design. The replacement of Leu with Pro at position 4 of decapeptide 9 afforded an antagonist of NPY in HEL cells (18, TyrIleAsnProIleTyrArgLeuArgTyr-NH2; IC50 = 100 +/- 5 nM). Deletion of the N-terminal tyrosine of 18 resulted in a 10-fold improvement in antagonistic activity with a parallel 4-fold decrease in Y2 affinity. This potent antagonist may provide further insight into the physiological role(s) for NPY in the mammalian and peripheral nervous system.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7707318     DOI: 10.1021/jm00007a012

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist.

Authors:  Y Dumont; A Cadieux; H Doods; L H Pheng; R Abounader; E Hamel; D Jacques; D Regoli; R Quirion
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

2.  Surface masking shapes the traffic of the neuropeptide Y Y2 receptor.

Authors:  Michael S Parker; Renu Sah; Steven L Parker
Journal:  Peptides       Date:  2012-06-23       Impact factor: 3.750

3.  NPY receptors as potential targets for anti-obesity drug development.

Authors:  Ernie Yulyaningsih; Lei Zhang; Herbert Herzog; Amanda Sainsbury
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

Review 4.  Neuronal and non-neuronal modulation of sympathetic neurovascular transmission.

Authors:  H Macarthur; G H Wilken; T C Westfall; L L Kolo
Journal:  Acta Physiol (Oxf)       Date:  2011-03-01       Impact factor: 6.311

5.  High-affinity neuropeptide Y receptor antagonists.

Authors:  A J Daniels; J E Matthews; R J Slepetis; M Jansen; O H Viveros; A Tadepalli; W Harrington; D Heyer; A Landavazo; J J Leban; A Spaltenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

6.  Novel dimeric DOTA-coupled peptidic Y1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers.

Authors:  David Chatenet; Renzo Cescato; Beatrice Waser; Judit Erchegyi; Jean E Rivier; Jean Claude Reubi
Journal:  EJNMMI Res       Date:  2011-09-02       Impact factor: 3.138

7.  Neuropeptide Y receptors: a promising target for cancer imaging and therapy.

Authors:  Juan Li; Yuchen Tian; Aiguo Wu
Journal:  Regen Biomater       Date:  2015-08-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.